Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIORESAL vs CYCLOBENZAPRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
FDA-approved: Intrathecal: severe spasticity of cerebral or spinal origin; Oral: spasticity in multiple sclerosis, spinal cord injury. Off-label: Trigeminal neuralgia, essential tremor, chronic hiccups, alcohol withdrawal, stiff-person syndrome, dystonia, gastroesophageal reflux disease, epilepsy, autism, cluster headaches, intractable hiccups, cocaine dependence, Huntington disease, Tourette syndrome, tardive dyskinesia, periodic limb movement disorder, myoclonus, apraxia of eyelid opening, hemifacial spasm, nystagmus, tic disorders, generalized anxiety disorder, insomnia, and chronic hiccup.
Treatment of muscle spasm associated with acute, painful musculoskeletal conditions (FDA approved),Adjunct to rest and physical therapy for relief of muscle spasm (FDA approved)
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Hepatic metabolism via deamination (minor pathway); primarily excreted unchanged in urine (70-80% as parent drug, 15% as metabolites).
Hepatic metabolism primarily via CYP3A4, CYP1A2, and CYP2D6; also undergoes N-demethylation and glucuronidation. Active metabolites include norcyclobenzaprine.
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
~30%; primarily bound to albumin.
~93% bound to albumin and alpha-1-acid glycoprotein.
0.5-1.0 L/kg; indicates moderate tissue distribution, with higher CNS penetration when administered intrathecally.
~5 L/kg (range 3–7 L/kg). Clinical meaning: extensive tissue distribution, including central nervous system.
Oral: 70-80% (first-pass effect minimal); intrathecal: nearly 100% due to direct CSF administration.
Oral: 33–55% due to first-pass metabolism; lower for immediate-release compared to extended-release (same extent but slower absorption).
GFR >60 m L/min: no adjustment; GFR 30-60: reduce dose by 25-50%; GFR <30: avoid or reduce by 75%; hemodialysis: supplement dose after dialysis.
No specific dosing adjustment recommended; use caution in severe renal impairment due to potential accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A or B: No adjustment. Child-Pugh Class C: Contraindicated due to risk of toxicity (minimal data). Use with caution in mild to moderate impairment; consider lower starting dose.
Oral: 2.5 mg 4 times daily initially, increase by 2.5-5 mg every 3 days to max 40 mg/day (2-7 years) or 60 mg/day (8-15 years). Intrathecal: test dose 25-50 mcg; maintenance 100-1000 mcg/day.
Not recommended for children under 15 years; safety and efficacy not established. For adolescents ≥15 years: same as adult dosing.
Start at 5 mg twice daily; increase slowly due to increased CNS sensitivity; monitor for sedation and confusion.
Start with 5 mg once daily; increase slowly to a maximum of 10 mg three times daily over 2 weeks. Increased sensitivity; monitor for anticholinergic effects and sedation.
Abrupt discontinuation of intrathecal baclofen may result in life-threatening withdrawal reactions (high fever, altered mental status, severe spasticity, rhabdomyolysis, autonomic dysfunction).
None
Abrupt discontinuation: may cause withdrawal symptoms (hallucinations, seizures, hyperthermia, rebound spasticity). Sedation: may impair ability to drive or operate machinery. Renal impairment: dose adjustment required. Avoid concomitant use with CNS depressants (alcohol, benzodiazepines). Caution in stroke patients, respiratory depression, psychiatric disorders, epilepsy, and pregnancy.
Serotonin syndrome risk, especially with concomitant serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs),Sedation and impairment of motor skills; caution with driving or operating machinery,Anticholinergic effects (e.g., urinary retention, angle-closure glaucoma, constipation),Cardiovascular effects: tachycardia, QT prolongation, arrhythmias (especially in elderly or with pre-existing heart disease),Hepatic impairment: use with caution; reduced clearance in mild impairment, avoid in severe impairment,Withdrawal symptoms after abrupt discontinuation: dysphoria, anxiety, insomnia,Elderly patients: increased risk of falls, confusion, anticholinergic toxicity
Absolute: Hypersensitivity to baclofen or any component; concomitant use of oral baclofen and intrathecal baclofen; intrathecal use contraindicated in patients with IV access device infection, spinal canal obstruction, or bleeding diathesis. Relative: Renal impairment, hepatic impairment, respiratory insufficiency, seizure disorder, history of autonomic dysreflexia, pregnancy, and lactation.
Hypersensitivity to cyclobenzaprine or any component of the formulation,Concomitant use or within 14 days of MAO inhibitors (hypertensive crisis risk),Acute recovery phase after myocardial infarction,Arrhythmias, heart block, or conduction disturbances,Hyperthyroidism,Severe hepatic impairment
No specific food interactions, but take with or without food consistently to avoid variable absorption.
Alcohol should be avoided due to additive CNS depression. Grapefruit juice may increase cyclobenzaprine levels (though data is limited, caution is advised). High-fat meals may delay absorption but not clinically significant. No specific dietary restrictions are required.
First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia, and withdrawal symptoms (irritability, tremors) in neonates. Use only if benefit outweighs risk.
Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. First trimester: Limited human data, but no structural anomalies reported. Second trimester: No specific adverse effects documented. Third trimester: Potential for neonatal withdrawal symptoms (e.g., jitteriness, respiratory depression) if used near term.
Lioresal (baclofen) is excreted into human breast milk in low concentrations; M/P ratio is approximately 0.4-0.7. No adverse effects reported in nursing infants. Caution advised, especially in preterm infants or those with renal impairment.
Cyclobenzaprine is excreted into breast milk in low amounts; the M/P ratio is unknown. Due to its anticholinergic effects, there is potential for adverse effects in the nursing infant (e.g., sedation, constipation). The American Academy of Pediatrics considers it compatible with breastfeeding, but caution is advised; alternatives may be preferred.
Increased clearance and volume of distribution during pregnancy may require dose adjustments. Dose should be titrated to lowest effective dose, with close monitoring for efficacy and toxicity. No specific dose adjustment guidelines; individualize based on clinical response.
No specific dose adjustments are recommended during pregnancy. Pharmacokinetic parameters (e.g., clearance) are not significantly altered by pregnancy. Use the lowest effective dose for the shortest duration due to lack of safety data.
Titrate slowly to avoid sedation and muscle weakness; monitor for withdrawal signs after abrupt discontinuation (e.g., spasticity rebound, hyperpyrexia, seizures). Intrathecal pump requires specialist management.
Cyclobenzaprine is structurally related to tricyclic antidepressants and shares similar anticholinergic and sedative properties. Onset of action for muscle relaxation is typically 1 hour, but maximal effect may take several days. Avoid use in patients with hyperthyroidism, cardiac disease, or those on MAOIs. Not recommended for use longer than 2-3 weeks due to lack of evidence for chronic use. Caution in elderly due to anticholinergic effects and fall risk.
Take exactly as prescribed; do not suddenly stop taking this medication.,Avoid alcohol and other CNS depressants.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Report any unusual muscle weakness, confusion, or difficulty breathing.,Keep medication in original container away from moisture and heat.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not drink alcohol or use other CNS depressants (e.g., benzodiazepines, opioids) while taking this medication, as it may increase sedation.,Take this medication exactly as prescribed, usually 3 times a day. Do not take more or less than directed.,This medication is intended for short-term use (up to 2-3 weeks) for muscle spasm. Do not use it for longer without consulting your doctor.,If you experience dry mouth, try sucking on sugar-free candy or ice chips. If you have difficulty urinating or vision changes, contact your doctor.,Do not stop taking this medication abruptly without consulting your doctor, although withdrawal is uncommon with short-term use.
No interactions on record
"The combination of cyclobenzaprine and carbinoxamine results in additive central nervous system depression due to their shared anticholinergic and sedative properties. This can lead to excessive sedation, impaired cognitive and motor function, and increased risk of falls or accidents. Severe cases may result in respiratory depression, especially in elderly patients or those with preexisting conditions."
"Cyclobenzaprine, a centrally acting muscle relaxant with tricyclic antidepressant (TCA)-like structure, and Dezocine, an opioid partial agonist analgesic with mu-opioid receptor activity, both depress the central nervous system (CNS) and have additive serotonergic effects. Concomitant use increases the risk of excessive CNS depression, manifesting as sedation, respiratory depression, and impaired psychomotor function, as well as potential serotonin syndrome due to combined serotonergic activity. Clinically, patients may experience profound drowsiness, confusion, respiratory compromise, and in severe cases, coma or death from respiratory failure."
"Lumacaftor, a potent inducer of cytochrome P450 (CYP) 3A4, significantly reduces the systemic exposure of cyclobenzaprine, a CYP3A4 substrate. This results in decreased plasma concentrations of cyclobenzaprine, potentially leading to reduced therapeutic efficacy for muscle spasm relief. Patients may require dose adjustments or alternative therapies to maintain clinical benefit."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIORESAL vs CYCLOBENZAPRINE HYDROCHLORIDE, answered by our medical review team.
LIORESAL is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.. CYCLOBENZAPRINE HYDROCHLORIDE is a Skeletal Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIORESAL and CYCLOBENZAPRINE HYDROCHLORIDE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIORESAL is: Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.. The standard adult dose of CYCLOBENZAPRINE HYDROCHLORIDE is: Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIORESAL and CYCLOBENZAPRINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIORESAL is classified as Category C. First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia. CYCLOBENZAPRINE HYDROCHLORIDE is classified as Category A/B. Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.